The transition from inflammation to cancer in the liver.
作者信息
Villanueva Augusto, Luedde Tom
机构信息
Division of Liver Diseases, Liver Cancer Program, Department of Medicine, Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York NY.
Division of Hematology/Medical Oncology, Department of Medicine Icahn School of Medicine at Mount Sinai New York NY.
出版信息
Clin Liver Dis (Hoboken). 2016 Oct 27;8(4):89-93. doi: 10.1002/cld.578. eCollection 2016 Oct.
Abstract
摘要
相似文献
1
The transition from inflammation to cancer in the liver.肝脏中从炎症到癌症的转变。
Clin Liver Dis (Hoboken). 2016 Oct 27;8(4):89-93. doi: 10.1002/cld.578. eCollection 2016 Oct.
2
Cajanus cajan ameliorated CCl-induced oxidative stress in Wistar rats via the combined mechanisms of anti-inflammation and mitochondrial-membrane transition pore inhibition.刺桐通过抗炎和抑制线粒体膜转换孔的联合机制改善 CCl 诱导的 Wistar 大鼠氧化应激。
J Ethnopharmacol. 2022 May 10;289:114920. doi: 10.1016/j.jep.2021.114920. Epub 2022 Jan 13.
3
Immune Cell Types and Secreted Factors Contributing to Inflammation-to-Cancer Transition and Immune Therapy Response.促进炎症向癌症转化和免疫治疗反应的免疫细胞类型和分泌因子。
Cell Rep. 2019 Feb 12;26(7):1965-1977.e4. doi: 10.1016/j.celrep.2019.01.080.
4
Pathogenesis from Inflammation to Cancer in NASH-Derived HCC.非酒精性脂肪性肝炎相关肝细胞癌中从炎症到癌症的发病机制
J Hepatocell Carcinoma. 2022 Aug 26;9:855-867. doi: 10.2147/JHC.S377768. eCollection 2022.
5
Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin-Related Modifier (SUMO)ylation-Related Suppression of NF-κB/Snail Signaling Pathway and Epithelial-Mesenchymal Transition.中脑星形胶质细胞衍生神经营养因子通过小泛素相关修饰物（SUMO）化相关抑制 NF-κB/Snail 信号通路和上皮-间充质转化抑制肝癌。
Hepatology. 2020 Apr;71(4):1262-1278. doi: 10.1002/hep.30917. Epub 2020 Jan 26.
6
Repression of let-7a cluster prevents adhesion of colorectal cancer cells by enforcing a mesenchymal phenotype in presence of liver inflammation.肝炎症存在时，let-7a 簇的抑制可通过强制形成间充质表型来防止结直肠癌细胞黏附。
Cell Death Dis. 2018 May 1;9(5):489. doi: 10.1038/s41419-018-0477-1.
7
IL6-mediated inflammatory loop reprograms normal to epithelial-mesenchymal transition metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta-deficient β2-spectrin mice.白细胞介素6介导的炎症循环使转化生长因子β缺陷型β2-血影蛋白小鼠的癌前肝脏中的正常上皮细胞重编程为上皮-间质转化转移性癌症干细胞。
Hepatology. 2017 Apr;65(4):1222-1236. doi: 10.1002/hep.28951. Epub 2017 Jan 20.
8
Temporal profiles describing markers of inflammation and metabolism during the transition period of pasture-based, seasonal-calving dairy cows.描述基于牧场、季节性产犊奶牛过渡期间炎症和代谢标志物的时间曲线。
J Dairy Sci. 2022 Mar;105(3):2669-2698. doi: 10.3168/jds.2021-20883. Epub 2022 Jan 5.
9
Changes of Th17/Treg ratio in the transition of chronic hepatitis B to liver cirrhosis and correlations with liver function and inflammation.慢性乙型肝炎向肝硬化转变过程中Th17/Treg比值的变化及其与肝功能和炎症的相关性
Exp Ther Med. 2019 Apr;17(4):2963-2968. doi: 10.3892/etm.2019.7299. Epub 2019 Feb 22.
10
The role of inflammation and liver cancer.炎症与肝癌的关系。
Adv Exp Med Biol. 2014;816:401-35. doi: 10.1007/978-3-0348-0837-8_16.
引用本文的文献
1
Effect of L. (saffron) and L. (rosemary) in hepatocellular carcinoma: A narrative review of current evidence and prospects.藏红花和迷迭香在肝细胞癌中的作用：当前证据与前景的叙述性综述
Iran J Basic Med Sci. 2025;28(8):986-1003. doi: 10.22038/ijbms.2025.84172.18204.
2
Hepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances.肝细胞癌：发病机制、分子机制及治疗进展
Front Oncol. 2025 Apr 8;15:1526206. doi: 10.3389/fonc.2025.1526206. eCollection 2025.
3
Hepatocellular Carcinoma in Patients with Chronic Hepatitis C and Liver Cirrhosis Treated with DAA: A Focused Review.接受直接抗病毒药物治疗的慢性丙型肝炎和肝硬化患者的肝细胞癌：重点综述
J Clin Med. 2025 Feb 24;14(5):1505. doi: 10.3390/jcm14051505.
4
Novel insights into the impact of liver inflammatory responses on primary liver cancer development.关于肝脏炎症反应对原发性肝癌发展影响的新见解。
Liver Res. 2023 Feb 3;7(1):26-34. doi: 10.1016/j.livres.2023.01.001. eCollection 2023 Mar.
5
Machine-Learning-Based Identification of Key Feature RNA-Signature Linked to Diagnosis of Hepatocellular Carcinoma.基于机器学习的与肝细胞癌诊断相关的关键特征RNA标志物识别
J Clin Exp Hepatol. 2024 Nov-Dec;14(6):101456. doi: 10.1016/j.jceh.2024.101456. Epub 2024 Jun 14.
6
Interleukin-6 in Hepatocellular Carcinoma: A Dualistic Point of View.肝细胞癌中的白细胞介素-6：一种二元观点
Biomedicines. 2023 Sep 24;11(10):2623. doi: 10.3390/biomedicines11102623.
7
Cytokines and Hepatocellular Carcinoma: Biomarkers of a Deadly Embrace.细胞因子与肝细胞癌：致命关联的生物标志物
J Pers Med. 2022 Dec 20;13(1):5. doi: 10.3390/jpm13010005.
8
Senolytic treatment reduces cell senescence and necroptosis in Sod1 knockout mice that is associated with reduced inflammation and hepatocellular carcinoma.衰老细胞清除治疗可减少 Sod1 敲除小鼠的细胞衰老和坏死性细胞凋亡，与炎症和肝细胞癌的减少有关。
Aging Cell. 2022 Aug;21(8):e13676. doi: 10.1111/acel.13676. Epub 2022 Jul 23.
9
Extracellular Vesicles from Steatotic Hepatocytes Provoke Pro-Fibrotic Responses in Cultured Stellate Cells.脂肪变性肝细胞来源的细胞外囊泡在体外诱导肝星状细胞产生促纤维化反应。
Biomolecules. 2022 May 13;12(5):698. doi: 10.3390/biom12050698.
10
Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification.肝细胞癌（HCC）：流行病学、病因学和分子分类。
Adv Cancer Res. 2021;149:1-61. doi: 10.1016/bs.acr.2020.10.001. Epub 2020 Nov 28.
本文引用的文献
1
Necroptosis in Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎中的坏死性凋亡
Cell Mol Gastroenterol Hepatol. 2015 Mar 12;1(3):264-265. doi: 10.1016/j.jcmgh.2015.02.001. eCollection 2015 May.
2
Hepatocellular carcinoma.肝细胞癌。
Nat Rev Dis Primers. 2016 Apr 14;2:16018. doi: 10.1038/nrdp.2016.18.
3
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.接受无干扰素治疗的丙型肝炎相关 HCC 患者早期肿瘤复发率高。
J Hepatol. 2016 Oct;65(4):719-726. doi: 10.1016/j.jhep.2016.04.008. Epub 2016 Apr 13.
4
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.PAGE-B 预测了慢性乙型肝炎患者在接受 5 年抗病毒治疗后发生肝细胞癌的风险。
J Hepatol. 2016 Apr;64(4):800-6. doi: 10.1016/j.jhep.2015.11.035. Epub 2015 Dec 8.
5
Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma.异位淋巴样结构作为肝细胞癌中肿瘤祖细胞的微环境。
Nat Immunol. 2015 Dec;16(12):1235-44. doi: 10.1038/ni.3290. Epub 2015 Oct 26.
6
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.索拉非尼辅助治疗肝细胞癌切除术后或消融后（STORM）：一项 3 期、随机、双盲、安慰剂对照试验。
Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.
7
Immunity, inflammation, and cancer: an eternal fight between good and evil.免疫、炎症与癌症：善恶之间的永恒斗争。
J Clin Invest. 2015 Sep;125(9):3347-55. doi: 10.1172/JCI80007. Epub 2015 Sep 1.
8
Cell death and cell death responses in liver disease: mechanisms and clinical relevance.肝病中的细胞死亡及细胞死亡反应：机制与临床意义
Gastroenterology. 2014 Oct;147(4):765-783.e4. doi: 10.1053/j.gastro.2014.07.018. Epub 2014 Jul 18.
9
The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.泛半胱天冬酶抑制剂恩瑞卡森（IDN-6556）可减轻非酒精性脂肪性肝炎小鼠模型中的肝损伤和纤维化。
Liver Int. 2015 Mar;35(3):953-66. doi: 10.1111/liv.12570. Epub 2014 Jun 6.
10
RIP3 inhibits inflammatory hepatocarcinogenesis but promotes cholestasis by controlling caspase-8- and JNK-dependent compensatory cell proliferation.RIP3 通过控制半胱天冬酶-8 和 JNK 依赖性代偿性细胞增殖来抑制炎症性肝癌发生，但促进胆汁淤积。
Cell Rep. 2013 Aug 29;4(4):776-90. doi: 10.1016/j.celrep.2013.07.035. Epub 2013 Aug 22.
Zotero 插件